Certara, Inc. (NASDAQ:CERT) Position Increased by Kopion Asset Management LLC

Kopion Asset Management LLC raised its position in Certara, Inc. (NASDAQ:CERT) by 46.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 555,643 shares of the company’s stock after buying an additional 175,005 shares during the quarter. Certara makes up approximately 4.2% of Kopion Asset Management LLC’s holdings, making the stock its 14th largest holding. Kopion Asset Management LLC’s holdings in Certara were worth $5,918,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wasatch Advisors LP raised its position in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after acquiring an additional 1,651,076 shares in the last quarter. Geneva Capital Management LLC increased its position in Certara by 0.7% during the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after buying an additional 37,392 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after buying an additional 1,128,006 shares during the last quarter. State Street Corp increased its holdings in shares of Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after acquiring an additional 122,411 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after acquiring an additional 273,095 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CERT. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Finally, Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $15.92.

Certara Stock Performance

CERT stock traded up $0.53 during trading on Wednesday, reaching $11.27. 104,860 shares of the stock were exchanged, compared to its average volume of 785,986. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.81 billion, a P/E ratio of -56.35, a price-to-earnings-growth ratio of 5.86 and a beta of 1.52. The stock has a 50 day simple moving average of $10.86 and a 200-day simple moving average of $11.95.

Certara (NASDAQ:CERT) last posted its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the previous year, the firm posted $0.06 earnings per share. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.